MX2021000408A - Antagonistas de los receptores p2x3. - Google Patents
Antagonistas de los receptores p2x3.Info
- Publication number
- MX2021000408A MX2021000408A MX2021000408A MX2021000408A MX2021000408A MX 2021000408 A MX2021000408 A MX 2021000408A MX 2021000408 A MX2021000408 A MX 2021000408A MX 2021000408 A MX2021000408 A MX 2021000408A MX 2021000408 A MX2021000408 A MX 2021000408A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- treatment
- compounds
- pain
- general
- Prior art date
Links
- 102100040460 P2X purinoceptor 3 Human genes 0.000 title 1
- 101710189970 P2X purinoceptor 3 Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000002193 Pain Diseases 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010011796 Cystitis interstitial Diseases 0.000 abstract 1
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 1
- 208000005615 Interstitial Cystitis Diseases 0.000 abstract 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 1
- 208000025609 Urogenital disease Diseases 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 206010013990 dysuria Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000020629 overactive bladder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 210000001835 viscera Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Esta invención se refiere a compuestos de fórmula I; (ver Fórmula) y sus usos como antagonistas de la actividad del receptor P2X3 y P2X2/3, composiciones farmacéuticas que comprenden dichos compuestos y métodos de tratamiento con los mismos. Los compuestos de la invención se pueden utilizar para el tratamiento y/o prevención del dolor y del dolor crónico y la tolerancia a analgésicos, trastornos y disfunciones respiratorias, y tratamiento de vejiga hiperactiva, síndrome de dolor de vejiga, disuria y en general en enfermedades genitourinarias, trastornos cardiovasculares y más en general para el tratamiento potencial de enfermedades y trastornos de órganos viscerales caracterizados por la participación de los receptores P2X3 y P2X2/3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1811452.0A GB2575490A (en) | 2018-07-12 | 2018-07-12 | P2X3 receptor antagonists |
| PCT/EP2019/068681 WO2020011921A1 (en) | 2018-07-12 | 2019-07-11 | P2x3 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000408A true MX2021000408A (es) | 2021-05-31 |
Family
ID=63273324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000408A MX2021000408A (es) | 2018-07-12 | 2019-07-11 | Antagonistas de los receptores p2x3. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11999732B2 (es) |
| EP (1) | EP3820566A1 (es) |
| JP (1) | JP7418396B2 (es) |
| KR (1) | KR20210031925A (es) |
| CN (1) | CN112584898B (es) |
| AU (1) | AU2019300335A1 (es) |
| BR (1) | BR112021000103A2 (es) |
| CA (1) | CA3106131A1 (es) |
| EA (1) | EA202190215A1 (es) |
| GB (1) | GB2575490A (es) |
| IL (1) | IL279960B2 (es) |
| MX (1) | MX2021000408A (es) |
| SG (1) | SG11202100026WA (es) |
| WO (1) | WO2020011921A1 (es) |
| ZA (1) | ZA202007980B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112778311B (zh) * | 2019-11-01 | 2024-06-04 | 上海翰森生物医药科技有限公司 | 含氮并环类衍生物抑制剂、其制备方法和应用 |
| WO2022175514A1 (en) | 2021-02-22 | 2022-08-25 | Bayer Aktiengesellschaft | N-(pyridin-2-yl)-acetamides as p2x3 inhibitors |
| CN114516826A (zh) * | 2022-02-21 | 2022-05-20 | 八叶草健康产业研究院(厦门)有限公司 | 一种褪黑素的制备方法 |
| EP4389746A3 (en) * | 2022-12-21 | 2024-07-03 | Recordati Industria Chimica E Farmaceutica SPA | P2x3 receptor antagonists |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3982000A (en) * | 1973-01-19 | 1976-09-21 | Sandoz, Inc. | Alkyl-substituted-tricyclic quinazolinones as bronchodilators |
| DE3046366A1 (de) * | 1980-12-09 | 1982-07-08 | Bayer Ag, 5090 Leverkusen | Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung |
| DE3146599A1 (de) * | 1981-11-25 | 1983-07-07 | Basf Ag, 6700 Ludwigshafen | Neue triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen |
| US4713383A (en) * | 1984-10-01 | 1987-12-15 | Ciba-Geigy Corporation | Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses |
| EP0181282A1 (de) * | 1984-10-01 | 1986-05-14 | Ciba-Geigy Ag | Triazolochinazolinverbindungen |
| WO1988002370A1 (en) | 1986-09-30 | 1988-04-07 | Ciba-Geigy Ag | 2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines pharmaceutical compositions and uses thereof |
| US5212310A (en) * | 1991-12-19 | 1993-05-18 | Neurogen Corporation | Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands |
| US5792766A (en) * | 1996-03-13 | 1998-08-11 | Neurogen Corporation | Imidazo 1,5-c! quinazolines; a new class of GABA brain receptor ligands |
| US6013650A (en) * | 1996-03-14 | 2000-01-11 | Neurogen Corporation | Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands |
| IT1303272B1 (it) * | 1998-10-29 | 2000-11-06 | Zambon Spa | Derivati triciclici inibitori della fosfodiesterasi 4 |
| GB9824897D0 (en) | 1998-11-12 | 1999-01-06 | Merck Sharp & Dohme | Therapeutic compounds |
| JP2001160488A (ja) | 1999-12-01 | 2001-06-12 | Konica Corp | 有機エレクトロルミネッセンス素子 |
| PL202623B1 (pl) | 2000-06-28 | 2009-07-31 | Smithkline Beecham Plc | Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna |
| EP1471066A1 (en) * | 2003-04-24 | 2004-10-27 | Aventis Pharma Deutschland GmbH | Triaza- and tetraaza-anthracenedione derivates, their preparation and their use as pharmaceuticals |
| JPWO2005077953A1 (ja) | 2004-02-18 | 2007-10-18 | 萬有製薬株式会社 | 含窒素縮合ヘテロ芳香環誘導体 |
| WO2011017142A1 (en) | 2009-08-06 | 2011-02-10 | Merck Patent Gmbh | Novel bicyclic urea compounds |
| JP5423363B2 (ja) | 2009-12-07 | 2014-02-19 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子、表示装置及び照明装置 |
| AU2012316912B9 (en) * | 2011-09-30 | 2017-04-27 | C&C Research Laboratories | Novel heterocyclic derivatives and their uses |
| JP6240180B2 (ja) * | 2012-06-18 | 2017-11-29 | ダート・ニューロサイエンス・（ケイマン）・リミテッド | 置換チオフェン−およびフラン−縮合アゾロピリミジン−５−（６ｈ）−オン化合物 |
| GB201406486D0 (en) * | 2014-04-10 | 2014-05-28 | Redx Pharma Ltd | Antibacterial compounds |
| US20160083400A1 (en) * | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
| WO2017046603A1 (en) * | 2015-09-18 | 2017-03-23 | Redx Pharma Plc | Antibacterial compounds and new uses thereof |
| CN108178759B (zh) * | 2018-01-05 | 2020-06-09 | 上海瑞纷医药科技有限责任公司 | 一种α-肾上腺素受体拮抗剂的合成方法 |
-
2018
- 2018-07-12 GB GB1811452.0A patent/GB2575490A/en not_active Withdrawn
-
2019
- 2019-07-11 WO PCT/EP2019/068681 patent/WO2020011921A1/en unknown
- 2019-07-11 AU AU2019300335A patent/AU2019300335A1/en active Pending
- 2019-07-11 EA EA202190215A patent/EA202190215A1/ru unknown
- 2019-07-11 IL IL279960A patent/IL279960B2/en unknown
- 2019-07-11 US US17/259,511 patent/US11999732B2/en active Active
- 2019-07-11 EP EP19748719.2A patent/EP3820566A1/en active Pending
- 2019-07-11 SG SG11202100026WA patent/SG11202100026WA/en unknown
- 2019-07-11 CA CA3106131A patent/CA3106131A1/en active Pending
- 2019-07-11 CN CN201980046603.6A patent/CN112584898B/zh active Active
- 2019-07-11 JP JP2021500684A patent/JP7418396B2/ja active Active
- 2019-07-11 MX MX2021000408A patent/MX2021000408A/es unknown
- 2019-07-11 BR BR112021000103-4A patent/BR112021000103A2/pt unknown
- 2019-07-11 KR KR1020217003658A patent/KR20210031925A/ko not_active Application Discontinuation
-
2020
- 2020-12-21 ZA ZA2020/07980A patent/ZA202007980B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL279960B2 (en) | 2024-03-01 |
| US20210246139A1 (en) | 2021-08-12 |
| AU2019300335A1 (en) | 2021-01-28 |
| CA3106131A1 (en) | 2020-01-16 |
| GB2575490A (en) | 2020-01-15 |
| IL279960A (en) | 2021-03-01 |
| CN112584898B (zh) | 2024-01-26 |
| KR20210031925A (ko) | 2021-03-23 |
| GB201811452D0 (en) | 2018-08-29 |
| EP3820566A1 (en) | 2021-05-19 |
| WO2020011921A1 (en) | 2020-01-16 |
| SG11202100026WA (en) | 2021-01-28 |
| EA202190215A1 (ru) | 2021-04-15 |
| JP7418396B2 (ja) | 2024-01-19 |
| BR112021000103A2 (pt) | 2021-03-30 |
| IL279960B1 (en) | 2023-11-01 |
| US11999732B2 (en) | 2024-06-04 |
| JP2021524492A (ja) | 2021-09-13 |
| CN112584898A (zh) | 2021-03-30 |
| ZA202007980B (en) | 2022-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000408A (es) | Antagonistas de los receptores p2x3. | |
| MX2023014354A (es) | Compuestos del peptido tirosina tirosina ciclico como moduladores de receptores de neuropeptido y. | |
| CL2013003816A1 (es) | Compuestos derivados de carboxamida y urea que comprende pirazol aromatico sustituido, ligantes del receptor de vanilloide; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis del dolor, migraña, enfermedad de parkinson, trastornos gastrointestinales, osteoporosis, entre otras enfermedades. | |
| NO20074567L (no) | Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse | |
| DK1957484T3 (da) | Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser | |
| CR20220031A (es) | Inhibidores tricíclicos de kars dependientes de akr1c3 | |
| EA200970302A1 (ru) | Тиофенпиразолопиримидиновые соединения | |
| EA201100524A1 (ru) | Азаиндазолы в качестве антагонистов рецептора ccr1 | |
| MX2020010879A (es) | Carboxamidas biciclicas y metodos de uso de las mismas. | |
| DK1951659T3 (da) | Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf | |
| MX2020014156A (es) | Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4. | |
| JP2019535799A5 (es) | ||
| UA96764C2 (ru) | Производные бензимидазола, полезные в лечении расстройств, связанных с рецептором trpvl | |
| EA201691674A1 (ru) | 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина | |
| WO2016168553A8 (en) | Deuterated obeticholic acid | |
| MY201535A (en) | Therapeutic compounds | |
| NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
| NZ738990A (en) | Cgrp receptor antagonists | |
| BRPI0907220A2 (pt) | métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf | |
| MX2023005408A (es) | Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina. | |
| MX2023008330A (es) | Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos. | |
| WO2016168388A3 (en) | Therapies for obesity, diabetes and related indications | |
| EA201790072A1 (ru) | Производные 2-арил-4-гидрокси-1,3-тиазола для применения в качестве ингибиторов trpm8 в лечении невралгии, болей, хронической обструктивной болезни лёгких и астмы | |
| PH12021550143A1 (en) | Pyridopyrimidines as histamine h4-receptor inhibitors | |
| PH12017501736A1 (en) | Indole derivatives |